{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:56:30Z","timestamp":1789574190330,"version":"build-2803163510"},"reference-count":180,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001821","name":"Vienna Science and Technology Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.kint.2025.06.014","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:13:07Z","timestamp":1751562787000},"page":"669-685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A systematic literature review and meta-analysis evaluated modifiable risk factors for the development of BK polyoma virus\u2013associated complications"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-1275","authenticated-orcid":false,"given":"Michael","family":"Eder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-440X","authenticated-orcid":false,"given":"Alexander","family":"Kainz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Omic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6940-8010","authenticated-orcid":false,"given":"Christof","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Copic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille N.","family":"Kotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1930-8964","authenticated-orcid":false,"given":"Nassim","family":"Kamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wojciechowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-0423","authenticated-orcid":false,"given":"Hans H.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7544-6275","authenticated-orcid":false,"given":"Rainer","family":"Oberbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2025.06.014_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/TP.0000000000001066","article-title":"Viral origin, clinical course, and renal outcomes in patients with BK virus infection after living-donor renal transplantation","volume":"100","author":"Schwarz","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1097\/TP.0000000000004976","article-title":"The second international consensus guidelines on the management of BK polyomavirus in kidney transplantation","volume":"108","author":"Kotton","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/750836","article-title":"BK virus in kidney transplant recipients: the influence of immunosuppression","volume":"2011","author":"Barraclough","year":"2011","journal-title":"J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.12659\/AOT.882640","article-title":"BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes?","volume":"17","author":"Acott","year":"2012","journal-title":"Ann Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e31819cc383","article-title":"An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States","volume":"87","author":"Dharnidharka","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/ajt.14530","article-title":"Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States","volume":"18","author":"Gupta","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1432-2277.2009.00842.x","article-title":"Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States","volume":"22","author":"Schold","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib8","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1097\/TP.0000000000000890","article-title":"Risk factors for BK polyoma virus treatment and association of treatment with kidney transplant failure: insights from a paired kidney analysis","volume":"100","author":"Thangaraju","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jcv.2018.10.002","article-title":"Risk factors for BK virus viremia and nephropathy after kidney transplantation: a systematic review","volume":"109","author":"Demey","year":"2018","journal-title":"J Clin Virol"},{"key":"10.1016\/j.kint.2025.06.014_bib10","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.kint.2025.06.014_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/96bdb520-d704-45f0-a143-43a48552952e","article-title":"Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews","volume":"7","author":"Geersing","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.06.014_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001744","article-title":"Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist","volume":"11","author":"Moons","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.kint.2025.06.014_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2025.06.014_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor Package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.kint.2025.06.014_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1526924817699969","article-title":"The frequency and associated factors for BK virus infection in a center performing mainly living kidney transplantations","volume":"27","author":"Alagoz","year":"2017","journal-title":"Prog Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.TP.0000437671.78716.f3","article-title":"Polyomavirus BK viremia in kidney transplant recipients after desensitization with IVIG and rituximab","volume":"97","author":"Barbosa","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.transproceed.2006.11.001","article-title":"Prospective evaluation of BK virus DNAemia in renal transplant patients and their transplant outcome","volume":"39","author":"Basse","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib18","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1097\/TP.0b013e3182921995","article-title":"Risk factors for BK virus infection in the era of therapeutic drug monitoring","volume":"95","author":"Borni-Duval","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib19","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1600-6143.2005.00742.x","article-title":"Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction","volume":"5","author":"Brennan","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib20","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1600-6143.2005.00934.x","article-title":"A prospective longitudinal study of BK virus infection in 104 renal transplant recipients","volume":"5","author":"Bressollette-Bodin","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1432-2277.2012.01480.x","article-title":"Clinical usefulness of BK virus plasma quantitative PCR to prevent BK virus associated nephropathy","volume":"25","author":"Chung","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib22","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/tid.12467","article-title":"Onset and progression of de novo donor-specific anti-human leukocyte antigen antibodies after BK polyomavirus and preemptive immunosuppression reduction","volume":"17","author":"Dieplinger","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13071","article-title":"Impact of human leukocyte antigen and calculated panel reactive antibody on BK viremia in kidney transplant recipients: a single-center experience and literature review","volume":"21","author":"El-Husseini","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.15171\/jrip.2016.03","article-title":"BK virus nephropathy is not always alone","volume":"5","author":"Esmaili","year":"2016","journal-title":"J Renal Inj Prev"},{"key":"10.1016\/j.kint.2025.06.014_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.12998\/wjcc.v7.i3.270","article-title":"Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation","volume":"7","author":"Favi","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.kint.2025.06.014_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13432","article-title":"A case-control study to assess the role of polyomavirus in transplant complications: where do we stand?","volume":"22","author":"Garcia Urb\u00e1n","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178801","article-title":"A delicate balance between rejection and BK polyomavirus associated nephropathy; a retrospective cohort study in renal transplant recipients","volume":"12","author":"Gard","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.06.014_bib28","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ekir.2022.12.020","article-title":"Incidence, risk factors, and outcomes of kidney transplant recipients with BK polyomavirus-associated nephropathy","volume":"8","author":"Gately","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.06.014_bib29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1399-3062.2010.00566.x","article-title":"BK viremia surveillance after kidney transplant: single-center experience during a change from cyclosporine-to lower-dose tacrolimus-based primary immunosuppression regimen","volume":"13","author":"Geddes","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/jmv.22106","article-title":"A prospective longitudinal study of BK virus infection in 120 Czech renal transplant recipients","volume":"83","author":"Girmanova","year":"2011","journal-title":"J Med Virol"},{"key":"10.1016\/j.kint.2025.06.014_bib31","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12879-023-08043-z","article-title":"Characteristics, risk factors and outcome of BKV nephropathy in kidney transplant recipients: a case-control study","volume":"23","author":"Gras","year":"2023","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.transproceed.2022.10.063","article-title":"Is polyomavirus-associated nephropathy more common in kidney transplant recipients exposed to valganciclovir? A retrospective single center analysis","volume":"55","author":"Hellemans","year":"2023","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib33","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1600-6143.2012.04320.x","article-title":"Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study","volume":"13","author":"Hirsch","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5527\/wjn.v5.i6.497","article-title":"Outcomes of renal transplant recipients with BK virus infection and BK virus surveillance in the Auckland region from 2006 to 2012","volume":"5","author":"Hsiao","year":"2016","journal-title":"World J Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib35","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.transproceed.2014.08.036","article-title":"Risk factors for BK virus infection and BK virus\u2013associated nephropathy under the impact of intensive monitoring and pre-emptive immunosuppression reduction","volume":"46","author":"Huang","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/1471-2369-14-207","article-title":"BK viremia and polyomavirus nephropathy in 352 kidney transplants; risk factors and potential role of mTOR inhibition","volume":"14","author":"Jacobi","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib37","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.ki.5002247","article-title":"Polyomavirus-associated nephropathy risk in kidney transplants: the influence of recipient age and donor gender","volume":"71","author":"Khamash","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.014_bib38","doi-asserted-by":"crossref","DOI":"10.4414\/smw.2020.20354","article-title":"Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study","volume":"150","author":"Krisl","year":"2020","journal-title":"Swiss Med Wkly"},{"issue":"183","key":"10.1016\/j.kint.2025.06.014_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/ijcp.12666","article-title":"Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study","author":"Liu","year":"2015","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.kint.2025.06.014_bib40","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1111\/j.1600-6143.2005.00980.x","article-title":"Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients","volume":"5","author":"Kuypers","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib41","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1159\/000443514","article-title":"Screening algorithm for BK virus-associated nephropathy using sequential testing of urinary cytology: a probabilistic model analysis","volume":"42","author":"Ma","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.23876\/j.krcp.2018.37.2.167","article-title":"Long-term prognosis of BK virus-associated nephropathy in kidney transplant recipients","volume":"37","author":"Park","year":"2018","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.kint.2025.06.014_bib43","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3390\/pathogens11101138","article-title":"CC genotype of GNAS c.393C>T (rs7121) polymorphism has a protective effect against development of BK viremia and BKV-associated nephropathy after renal transplant","volume":"11","author":"Peitz","year":"2022","journal-title":"Pathogens"},{"key":"10.1016\/j.kint.2025.06.014_bib44","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1093\/ndt\/gfn671","article-title":"Risk factors for polyoma virus nephropathy","volume":"24","author":"Prince","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib45","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13915","article-title":"Incidence, risk factors, outcomes, and clinical management of BK viremia in the modern era of kidney transplantation","volume":"24","author":"Qeska","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib46","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/tid.12611","article-title":"Incidence of BK polyomavirus infection after kidney transplantation is independent of type of immunosuppressive therapy","volume":"18","author":"Radtke","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib47","first-page":"1970","article-title":"Viral load and duration of BK polyomavirus viraemia determine renal graft fibrosis progression: histologic evaluation of late protocol biopsies","volume":"34","author":"Reischig","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib48","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1681\/ASN.2014010119","article-title":"Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies","volume":"26","author":"Sawinski","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib49","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/tri.12601","article-title":"Different risk factor profiles distinguish early-onset from late-onset BKV-replication","volume":"28","author":"Schachtner","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib50","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jcv.2017.09.004","article-title":"BK virus replication in renal transplant recipients: analysis of potential risk factors may contribute in reactivation","volume":"96","author":"Shenagari","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.kint.2025.06.014_bib51","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1399-0012.2007.00677.x","article-title":"Association of treatment with 15-deoxyspergualin and BK virus nephropathy in kidney allograft recipients","volume":"21","author":"Shi","year":"2007","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib52","first-page":"52","article-title":"BK polyomavirus (BKV) infection and nephropathy in renal transplant recipients: a prospective study at tertiary care center","volume":"37","author":"Singh","year":"2016","journal-title":"Int J Pharm Sci Rev Res"},{"key":"10.1016\/j.kint.2025.06.014_bib53","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3109\/00365599.2012.726643","article-title":"Risk factors and interventional strategies for BK polyomavirus infection after renal transplantation","volume":"46","author":"Steubl","year":"2012","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib54","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/infdis\/jiw168","article-title":"MICA mutant A5.1 influences BK polyomavirus reactivation and associated nephropathy after kidney transplantation","volume":"214","author":"Tonnerre","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib55","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.TP.0000165110.78397.93","article-title":"Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients","volume":"80","author":"Toyoda","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib56","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/01.TP.0000438115.20198.89","article-title":"Association of interferon gamma gene polymorphisms with BK virus infection among hispanic renal allograft recipients","volume":"97","author":"Vu","year":"2014","journal-title":"Transplantation"},{"issue":"suppl 2","key":"10.1016\/j.kint.2025.06.014_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/tan.13645","article-title":"Combined association of recipient killer cell immunoglobulin-like haplotype AA and donor HLA-C\u221707 gene with BK virus associated nephropathy in kidney transplant patients","volume":"94","author":"Kovacevic Vojtusek","year":"2019","journal-title":"HLA"},{"key":"10.1016\/j.kint.2025.06.014_bib58","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/TP.0b013e3181bc6096","article-title":"Dendritic cell deficiency associated with development of BK viremia and nephropathy in renal transplant recipients","volume":"89","author":"Womer","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib59","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.transproceed.2008.06.025","article-title":"Early diagnosis of polyomavirus type BK infection in tailoring immunosuppression for kidney transplant patients: screening with urine qualitative polymerase chain reaction assay","volume":"40","author":"Wu","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib60","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/ajt.13880","article-title":"Pretransplantation donor\u2013recipient pair seroreactivity against BK polyomavirus predicts viremia and nephropathy after kidney transplantation","volume":"17","author":"Wunderink","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib61","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000759","article-title":"Prediction of early BK virus infection in kidney transplant recipients by the number of cells with intranuclear inclusion bodies (decoy cells)","volume":"4","author":"Yamada","year":"2018","journal-title":"Transplant Direct"},{"key":"10.1016\/j.kint.2025.06.014_bib62","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1399-0012.2008.00817.x","article-title":"The prevalence of BK polyomavirus infection in outpatient kidney transplant recipients followed in a single center","volume":"22","author":"Yeo","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib63","first-page":"727","article-title":"Predictive factors of BK virus development in kidney transplant recipients and the effect of low-dose tacrolimus plus everolimus on clinical outcomes","volume":"21","author":"Yilmaz","year":"2023","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib64","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.transproceed.2017.11.007","article-title":"BK virus\u2013associated nephropathy: current situation in a resource-limited country","volume":"50","author":"Yooprasert","year":"2018","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib65","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.transproceed.2009.01.036","article-title":"Reactivation of BK virus in the early period after kidney transplantation","volume":"41","author":"Ziedina","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib66","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.transproceed.2017.02.011","article-title":"Average tacrolimus trough level in the first month after transplantation may predict acute rejection","volume":"49","author":"Akt\u00fcrk","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib67","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.tp.0000251807.72246.7d","article-title":"Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies","volume":"83","author":"Cosio","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib68","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/tri.12134","article-title":"The impact of surveillance and rapid reduction in immunosuppression to control BK virus-related graft injury in kidney transplantation","volume":"26","author":"Elfadawy","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib69","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized study","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib70","doi-asserted-by":"crossref","first-page":"E596","DOI":"10.1111\/ctr.12040","article-title":"BK virus viremia in a well-HLA-matched kidney transplant population mainly on low-dose cyclosporine-based immunosuppression","volume":"26","author":"Helanter\u00e4","year":"2012","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib71","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14110","article-title":"The effect of human leukocyte antigen A1 and B35-Cw4 on sustained BK polyomavirus DNAemia after renal transplantation","volume":"34","author":"Hosseini-Moghaddam","year":"2020","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib72","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/tid.12051","article-title":"Ureteral stent placement and BK viremia in kidney transplant recipients","volume":"15","author":"Kayler","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib73","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12817","article-title":"Impact of low-level BK polyomavirus viremia on intermediate-term renal allograft function","volume":"20","author":"Korth","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib74","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1097\/TP.0000000000000149","article-title":"Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients","volume":"97","author":"Richards","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib75","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12681","article-title":"Stabilization of renal function after the first year of follow-up in kidney transplant recipients treated for significant BK polyomavirus infection or BK polyomavirus-associated nephropathy","volume":"19","author":"Simard-Meilleur","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib76","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/phar.1591","article-title":"African-American race modifies the influence of tacrolimus concentrations on acute rejection and toxicity in kidney transplant recipients","volume":"35","author":"Taber","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.kint.2025.06.014_bib77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.tp.0000269616.21698.10","article-title":"Ureteral stents: a novel risk factor for polyomavirus nephropathy","volume":"84","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib78","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/TP.0b013e3181aa8d93","article-title":"Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study","volume":"88","author":"Manitpisitkul","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib79","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/TP.0000000000001261","article-title":"Correlation of BK virus neutralizing serostatus with the incidence of BK viremia in kidney transplant recipients","volume":"101","author":"Abend","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib80","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1111\/j.1600-6143.2004.00563.x","article-title":"HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients","volume":"4","author":"Awadalla","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib81","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.tp.0000268524.27506.39","article-title":"BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes","volume":"84","author":"Benavides","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib82","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13768","article-title":"Risk factors and outcomes of BK viremia among deceased donor kidney transplant recipients based on donor characteristics","volume":"24","author":"Breyer","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4236\/ijcm.2016.73021","article-title":"Impact of maintenance steroids versus rapid steroid withdrawal in African-American kidney transplant recipients: comparison of two urban centers","volume":"7","author":"Chon","year":"2016","journal-title":"Int J Clin Med"},{"key":"10.1016\/j.kint.2025.06.014_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105430","article-title":"Composition of the neutralising antibody response predicts risk of BK virus DNAaemia in recipients of kidney transplants","volume":"110","author":"Chong","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.kint.2025.06.014_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177339","article-title":"Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients","volume":"12","author":"DeWolfe","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.06.014_bib86","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2215\/CJN.18101120","article-title":"Deceased-donor acute kidney injury and BK polyomavirus in kidney transplant recipients","volume":"16","author":"Hall","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib87","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.3390\/jcm10092005","article-title":"Clinical relevance of corticosteroid withdrawal on graft histological lesions in low-immunological-risk kidney transplant patients","volume":"10","author":"Hern\u00e1ndez","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.kint.2025.06.014_bib88","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/TP.0b013e31828423cd","article-title":"Screening for BK viremia reduces but does not eliminate the risk of BK nephropathy: a single-center retrospective analysis","volume":"95","author":"Knight","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib89","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/jpm14111106","article-title":"Precision in immune management: balancing steroid exposure, rejection risk, and infectious outcomes in adult kidney transplant recipients","volume":"14","author":"Koi","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.kint.2025.06.014_bib90","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1186\/s12879-024-09821-z","article-title":"The simultaneous presence of active BK, Epstein Barr, and human cytomegalovirus infection and their correlation by host factors in patients suspected of kidney transplant rejection","volume":"24","author":"Eslami","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib91","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/ctr.12829","article-title":"1,25 Dihydroxyvitamin D circulating levels, calcitriol administration, and incidence of acute rejection, CMV infection, and polyoma virus infection in renal transplant recipients","volume":"30","author":"Moscarelli","year":"2016","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1600-6143.2012.04314.x","article-title":"BK virus replication and nephropathy after alemtuzumab-induced kidney transplantation","volume":"13","author":"Theodoropoulos","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib93","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1016\/S0140-6736(16)32187-0","article-title":"Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial","volume":"388","author":"Thomusch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.06.014_bib94","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1016\/j.transproceed.2022.10.012","article-title":"Impact of BK polyomavirus plasma viral load in kidney transplant outcomes","volume":"54","author":"Alonso","year":"2022","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib95","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5500\/wjt.v7.i5.269","article-title":"Graft loss among renal-transplant recipients with early reduction of immunosuppression for BK viremia","volume":"7","author":"Azar","year":"2017","journal-title":"World J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib96","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12969","article-title":"Determination of viremia cut-off for risk to develop BKPyV-associated nephropathy among kidney transplant recipients","volume":"20","author":"Bicalho","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib97","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/ndt\/gfy346","article-title":"Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes","volume":"34","author":"Bischof","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib98","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13056","article-title":"Effect of polyoma viremia on 3-year allograft kidney function","volume":"21","author":"David-Neto","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib99","article-title":"Antiviral prophylaxis, male sex, and killer immunoglobulin-like receptor KIR2DL3 as markers for stratifying the risk of BK polyomavirus-associated nephropathy in kidney transplant recipients","volume":"133","author":"Deborska-Materkowsk","year":"2023","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.kint.2025.06.014_bib100","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13681","article-title":"Anti-IL-2R blockers comparing with polyclonal antibodies: higher risk of rejection without negative mid-term outcomes after ABO-incompatible kidney transplantation","volume":"33","author":"Del Bello","year":"2019","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib101","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.transproceed.2017.01.009","article-title":"Prevalence and risk factors of BK viremia in patients with kidney transplantation: a single-center experience from Turkey","volume":"49","author":"Dogan","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib102","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1432-2277.2009.01004.x","article-title":"Comparison of efficacy of induction therapy in low immunologic risk African-American kidney transplant recipients","volume":"23","author":"Fleming","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib103","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1590\/1678-4685-jbn-3776","article-title":"Quantitative detection of BK virus in kidney transplant recipients: a prospective validation study","volume":"40","author":"Pinto","year":"2018","journal-title":"J Bras Nefrol"},{"key":"10.1016\/j.kint.2025.06.014_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2019.114979","article-title":"Screening for BKV-DNAEMIA after renal transplantation in a resource limited setting","volume":"96","author":"de Almeida","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib105","first-page":"820","article-title":"Increased risk of rejection after basiliximab induction in sensitized kidney transplant recipients without pre-existing donor-specific antibodies\u2014a retrospective study","volume":"32","author":"Goumard","year":"2019","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib106","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.transproceed.2006.02.116","article-title":"Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab","volume":"38","author":"Heilman","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib107","doi-asserted-by":"crossref","first-page":"727","DOI":"10.6002\/ect.2018.0262","article-title":"Prevalence and risk factors of BK viremia and clinical impact of BK virus surveillance on outcomes in kidney transplant recipients: a single-center cross-sectional study","volume":"17","author":"Ji","year":"2019","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib108","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/infdis\/jiac440","article-title":"Urine exosomal bkv-miR-B1\u20135p and BK virus nephropathy in kidney transplant recipients","volume":"227","author":"Jung","year":"2023","journal-title":"J Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib109","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3390\/jcm9051320","article-title":"Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation","volume":"9","author":"Kim","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.kint.2025.06.014_bib110","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1111\/ajt.14282","article-title":"BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: first report from the Swiss Transplant Cohort Study","volume":"17","author":"Leboeuf","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib111","doi-asserted-by":"crossref","first-page":"623","DOI":"10.23876\/j.krcp.21.310","article-title":"Antithymocyte globulin versus basiliximab induction for kidney transplantation in elderly patients: matched analysis within the Korean multicentric registry","volume":"41","author":"Lee","year":"2022","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.kint.2025.06.014_bib112","article-title":"Risk factors for BK virus infection in DCD donor kidney transplant recipients","volume":"10","author":"Liu","year":"2023","journal-title":"Front Med"},{"key":"10.1016\/j.kint.2025.06.014_bib113","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.TP.0000437432.35227.3e","article-title":"Genomics of BK viremia in kidney transplant recipients","volume":"97","author":"Lubetzky","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib114","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1093\/ndt\/gft298","article-title":"HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia","volume":"28","author":"Masutani","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib115","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.transproceed.2008.01.068","article-title":"Renal retransplantation: a retrospective monocentric study","volume":"40","author":"Ott","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib116","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1016\/j.transproceed.2015.08.006","article-title":"Risk factors for the development of BK virus nephropathy in renal transplant recipients","volume":"47","author":"Pai","year":"2015","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib117","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/SLA.0000000000000496","article-title":"Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation","volume":"259","author":"Pilch","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.kint.2025.06.014_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15329","article-title":"Association of BKV viremia and nephropathy with adverse alloimmune outcomes in kidney transplant recipients","volume":"38","author":"Rampersad","year":"2024","journal-title":"Clin Transplantat"},{"key":"10.1016\/j.kint.2025.06.014_bib119","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/microorganisms12010065","article-title":"BKPyV DNAemia in kidney transplant recipients undergoing regular screening: a single-centre cohort study","volume":"12","author":"Rasmussen","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.kint.2025.06.014_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1492611","article-title":"Impact of induction agents and maintenance immunosuppression on torque teno virus loads and year-one complications after kidney transplantation","volume":"15","author":"Reineke","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.06.014_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.929946","article-title":"Pretransplantation seroreactivity in kidney donors and recipients as a predictive factor for posttransplant BKPyV-DNAemia","volume":"13","author":"Sal\u00e1kov\u00e1","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2025.06.014_bib122","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/TP.0000000000000507","article-title":"Clinical outcomes associated with induction regimens among retransplant kidney recipients in the United States","volume":"99","author":"Schold","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib123","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/TP.0b013e31823ec05a","article-title":"Lower prevalence of BK virus infection in African American renal transplant recipients: a prospective study","volume":"93","author":"Sood","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib124","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/tid.12347","article-title":"Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients","volume":"17","author":"Tohme","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib125","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.3390\/biomedicines11113060","article-title":"Risk factors for CMV and BK infections in an elderly veteran population following kidney transplantation: implications for immunosuppression induction and management","volume":"11","author":"Thorndyke","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.kint.2025.06.014_bib126","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12644","article-title":"Ureteral stent duration and the risk of BK polyomavirus viremia or bacteriuria after kidney transplantation","volume":"19","author":"Wingate","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib127","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12770","article-title":"BK polyomavirus infection after renal transplantation: surveillance in a resource-challenged setting","volume":"19","author":"Bagchi","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib128","doi-asserted-by":"crossref","first-page":"e08","DOI":"10.15171\/jnp.2020.08","article-title":"Comparison of clinical outcome of induction immunosuppressive therapy with thymoglobulin and standard therapy in kidney transplantation; a randomized double-blind clinical trial","volume":"9","author":"Shahbazian","year":"2020","journal-title":"J Nephropathol"},{"key":"10.1016\/j.kint.2025.06.014_bib129","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/TP.0b013e3181b4acfb","article-title":"A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation","volume":"88","author":"Farney","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib130","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.transproceed.2020.08.025","article-title":"Opportunistic infections after induction with alemtuzumab or basiliximab: a 3-year kidney transplantation experience","volume":"53","author":"Florescu","year":"2021","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib131","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): a randomised trial","volume":"384","author":"Friend","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2025.06.014_bib132","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70084","article-title":"BK polyomavirus DNAemia with a high DNA load is associated with de novo donor-specific HLA antibodies in kidney transplant recipients","volume":"96","author":"Moest","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.kint.2025.06.014_bib133","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/ctr.12532","article-title":"Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal","volume":"29","author":"Saull","year":"2015","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib134","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1432-2277.2008.00642.x","article-title":"Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death","volume":"21","author":"Schadde","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/tid.12135","article-title":"Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy","volume":"15","author":"Chung","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib136","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1093\/ndt\/gfr215","article-title":"Increase of infectious complications in ABO-incompatible kidney transplant recipients\u2014a single centre experience","volume":"26","author":"Habicht","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib137","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.2215\/CJN.03710411","article-title":"Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin","volume":"6","author":"Kahwaji","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146075","article-title":"Outcome after desensitization in HLA or ABO-incompatible kidney transplant recipients: a single center experience","volume":"11","author":"Kauke","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2025.06.014_bib139","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/TP.0b013e3181a235fd","article-title":"A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation","volume":"87","author":"Tyden","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib140","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.transproceed.2019.01.106","article-title":"Effects of rituximab on atherosclerotic biomarkers in kidney transplant recipients","volume":"51","author":"Aliyeva","year":"2019","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib141","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1590\/0001-3765201720160470","article-title":"Evaluation of the predisposition and clinical impact of BK virus replication in kidney transplant patients","volume":"89","author":"Moura","year":"2017","journal-title":"An Acad Bras Cienc"},{"key":"10.1016\/j.kint.2025.06.014_bib142","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early conversion from calcineurin inhibitor- to everolimus-based therapy following kidney transplantation: results of the randomized ELEVATE trial","volume":"17","author":"de Fijter","year":"2017","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib143","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib144","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.014_bib145","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib146","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12687","article-title":"Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine-, mycophenolate sodium-, or everolimus-based low-dose immunosuppressive therapy","volume":"19","author":"van Doesum","year":"2017","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib147","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3346\/jkms.2015.30.6.682","article-title":"A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk","volume":"30","author":"Lee","year":"2015","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.kint.2025.06.014_bib148","first-page":"212","article-title":"Prospective monitoring of cytomegalovirus, Epstein-Barr virus, BK virus, and JC virus infections on belatacept therapy after a kidney transplant","volume":"12","author":"Bassil","year":"2014","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib149","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14298","article-title":"Belatacept-based immunosuppression does not confer increased risk of BK polyomavirus-DNAemia relative to tacrolimus-based immunosuppression","volume":"26","author":"Eichenberger","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib150","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3390\/jcm8081164","article-title":"Efficacy and safety of belatacept treatment in renal allograft recipients at high cardiovascular risk\u2014a single center experience","volume":"8","author":"Neuwirt","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.kint.2025.06.014_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2023.101857","article-title":"Increased CMV disease and \u201csevere\u201d BK viremia with belatacept vs. sirolimus three-drug maintenance immunosuppression","volume":"79","author":"Petrossian","year":"2023","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.kint.2025.06.014_bib152","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101774","article-title":"Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens","volume":"76","author":"Chiodo Ortiz","year":"2023","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.kint.2025.06.014_bib153","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1097\/TP.0000000000000753","article-title":"Outcomes following ABO-incompatible kidney transplantation performed after desensitization by nonantigen-specific immunoadsorption","volume":"99","author":"Becker","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib154","doi-asserted-by":"crossref","first-page":"19","DOI":"10.15171\/jnp.2016.04","article-title":"Early post-transplant complications following ABO incompatible kidney transplantation","volume":"5","author":"Bennani","year":"2016","journal-title":"J Nephropathol"},{"key":"10.1016\/j.kint.2025.06.014_bib155","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4174\/astr.2016.91.1.37","article-title":"Ongoing higher infection rate in ABO-incompatible kidney transplant recipient: is it a serious problem? A single-center experience","volume":"91","author":"Choi","year":"2016","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.kint.2025.06.014_bib156","article-title":"Outcomes in AB0 incompatible living donor kidney transplantation: a case-control study","volume":"9","author":"Cozzi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2025.06.014_bib157","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/j.ekir.2024.04.003","article-title":"Polyomavirus nephropathy in ABO blood group-incompatible kidney transplantation: Torque Teno virus and immunosuppressive burden as an approximation to the problem","volume":"9","author":"Eder","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2025.06.014_bib158","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1600-6143.2011.03464.x","article-title":"Successful ABO-incompatible kidney transplantation with antibody removal and standard immunosuppression","volume":"11","author":"Flint","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib159","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1097\/TP.0b013e3181726849","article-title":"ABO-incompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up","volume":"85","author":"Genberg","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib160","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.transproceed.2013.11.114","article-title":"Association of DNA amplification with progress of BK polyomavirus infection and nephropathy in renal transplant recipients","volume":"46","author":"Hasegawa","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib161","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.transproceed.2013.08.038","article-title":"Comparative analysis of ABO-incompatible living donor kidney transplantation with ABO-compatible grafts: a single-center experience in Korea","volume":"45","author":"Hwang","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib162","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.927420","article-title":"Acute rejection and infectious complications in ABO- and HLA-incompatible kidney transplantations","volume":"25","author":"Ko","year":"2020","journal-title":"Ann Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib163","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004249","article-title":"Analysis of 4000 kidney transplantations in a single center: across immunological barriers","volume":"95","author":"Kwon","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2025.06.014_bib164","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12879-024-09093-7","article-title":"The risk factors associated with post-transplantation BKPyV nephropathy and BKPyV DNAemia: a prospective study in kidney transplant recipients","volume":"24","author":"Lorant","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.kint.2025.06.014_bib165","article-title":"Risk factors for developing BK virus-associated nephropathy: a single-center retrospective cohort study of kidney transplant recipients","volume":"27","author":"Lorant","year":"2022","journal-title":"Ann Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib166","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.2215\/CJN.00770112","article-title":"Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients","volume":"7","author":"Sharif","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib167","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5414\/CN109114","article-title":"Successful launch of an ABO-incompatible kidney transplantation program to overcome the shortage of compatible living donors: experience at a single center","volume":"88","author":"Song","year":"2017","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib168","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/ndt\/gfv388","article-title":"One hundred ABO-incompatible kidney transplantations between 2004 and 2014: a single-centre experience","volume":"31","author":"Zschiedrich","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib169","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/459747","article-title":"Ureteral stent placement increases the risk for developing BK viremia after kidney transplantation","volume":"2014","author":"Hashim","year":"2014","journal-title":"J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/tri.12888","article-title":"Ureteral stent placement and immediate graft function are associated with increased risk of BK viremia in the first year after kidney transplantation","volume":"30","author":"Maliakkal","year":"2017","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2025.06.014_bib171","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/j.transproceed.2011.06.034","article-title":"Ureteral stents: a risk factor for polyomavirus BK viremia in kidney transplant recipients undergoing protocol screening","volume":"43","author":"Siparsky","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.kint.2025.06.014_bib172","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000005399","article-title":"Donor variability and PD-1 expression limit BK polyomavirus-specific T-cell function and therapy","author":"Wilhelm","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib173","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/TP.0b013e3181bca422","article-title":"Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs","volume":"88","author":"Egli","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2025.06.014_bib174","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/ajt.13541","article-title":"BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12","volume":"16","author":"Hirsch","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2025.06.014_bib175","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.014_bib176","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2025.06.014_bib177","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.2215\/CJN.13221216","article-title":"CMV and BKPyV Infections in renal transplant recipients receiving an mTOR inhibitor-based regimen versus a CNI-based regimen: a systematic review and meta-analysis of randomized, controlled trials","volume":"12","author":"Mallat","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2025.06.014_bib178","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.kint.2024.09.018","article-title":"Insights from the BKEVER trial comparing everolimus versus mycophenolate mofetil for BK polyomavirus infection in kidney transplant recipients","volume":"107","author":"Caillard","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.014_bib179","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.kint.2024.10.019","article-title":"Can you have a cake and eat it? Comparing reducing mycophenolate versus switching to everolimus for kidney transplants with new-onset BKPyV-DNAemia","volume":"107","author":"Hirsch","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2025.06.014_bib180","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382500506X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382500506X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T09:40:59Z","timestamp":1758188459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525382500506X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":180,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S008525382500506X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2025.06.014","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic literature review and meta-analysis evaluated modifiable risk factors for the development of BK polyoma virus\u2013associated complications","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2025.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}